Clinical trial

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

NCT05640778

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-10-01

PhasePHASE2

Study timeline

Study start (actual)2022-10-01Date precision: day

Registry last updated2024-01-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Luminal B/HER2-negative Breast Cancerunresolved

Interventions

Dalpiciclib combined with aromatase inhibitorsDRUG

Sponsors & collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicinelead sponsor

GeneCast Biotechnology Co., Ltd.collaborator

Mapped research locations

HangzhouChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05640778 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.